Odanacatib
≈ 4 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443444475 | IUPAC_name = N-(1-Cyanocyclopropyl)-4-fluoro-N 2 - {(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}- L -leucinamide | image = Odanacatib corrected.svg | image_class = skin-invert-image | width = 300 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = By mouth | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 6478 | CAS_number_Ref = | CAS_number = 603139-19-1 | ATC_prefix = None | ATC_suffix = | ATC_supplemental = | PubChem = 10152654 | DrugBank_Ref = | DrugBank = | UNII_Ref = | UNII = N673F6W2VH | KEGG_Ref = | KEGG = D08955 | ChEMBL_Ref = | ChEMBL = 481611 | ChemSpiderID_Ref = | ChemSpiderID = 8328162 | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | smiles = CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F | StdInChI_Ref = | StdInChI = 1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = FWIVDMJALNEADT-SFTDATJTSA-N | synonyms = (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-…
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443444475 | IUPAC_name = N-(1-Cyanocyclopropyl)-4-fluoro-N 2 - {(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}- L -leucinamide | image = Odanacatib corrected.svg | image_class = skin-invert-image | width = 300 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = By mouth | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | IUPHAR_ligand = 6478 | CAS_number_Ref = | CAS_number = 603139-19-1 | ATC_prefix = None | ATC_suffix = | ATC_supplemental = | PubChem = 10152654 | DrugBank_Ref = | DrugBank = | UNII_Ref = | UNII = N673F6W2VH | KEGG_Ref = | KEGG = D08955 | ChEMBL_Ref = | ChEMBL = 481611 | ChemSpiderID_Ref = | ChemSpiderID = 8328162 | chemical_formula = | C=25 | H=27 | F=4 | N=3 | O=3 | S=1 | smiles = CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F | StdInChI_Ref = | StdInChI = 1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = FWIVDMJALNEADT-SFTDATJTSA-N | synonyms = (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2- {[(1S)-2,2,2-trifluoro-1- {4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide }} Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
The drug was developed by Merck & Co. The phase III clinical trial for this medicine was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015.
In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke. This drug was developed at Merck Frosst in Montreal.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1332195573 under CC BY-SA 4.0; modifications have been made.